Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Completed 9 enrolled Ludwig Institute for Cancer Research National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: A phase I trial to study the side effects of vaccine therapy in patients with ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Timeline

Start: 2003-06-23
Primary completion: 2006-05-09
Completion: 2013-08-01

Publications

Results Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res. 2008 May 1;14(9):2740-8. doi: 10.1158/1078-0432.CCR-07-4619.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NY-ESO-1b peptide	Vaccine	100 ug	Subcutaneous
Background	NY-ESO-1 peptide vaccine	Vaccine	0.5 ml	Subcutaneous

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Summary

Timeline

Publications

Drugs

Indications